Sodium-glucose cotransporter-2 inhibitors (SGLT2i), or gliflozins, are medications used in the treatment of type 2 diabetes mellitus (T2DM). They are designed to lower high blood glucose levels typical in T2DM, and work by inhibiting the sodium-glucose transport protein 2. SGLT2i have also been shown to improve outcomes among patients with chronic kidney disease, heart failure and coronary artery disease.
Go to Source
https://medicalxpress.com/rss-feed/